Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome

Annals of Neurology
C Michel Harper, A G Engel

Abstract

The slow-channel congenital myasthenic syndrome (SCCMS) is caused by gain of function mutations in subunits of the end-plate acetylcholine receptor (AChR). The mutations prolong the opening episodes of the AChR channel, leading to a depolarization block and an end-plate myopathy. Because levels of quinidine sulfate attainable in clinical practice shorten the opening episodes of genetically engineered mutant SCCMS receptors in vitro, we tested the notion that the drug can be of benefit in SCCMS. We treated 6 SCCMS patients with quinidine sulfate in an open-label trial, using objective clinical measures of muscle strength and repetitive stimulation studies as end points. One patient became allergic to quinidine after 7 days. The remaining patients tolerated the drug well and after 30 days of continuous therapy showed statistically significant improvement in muscle strength and in decrement of the compound muscle action potential elicited by rapid rates of stimulation.

References

Dec 7, 1989·The New England Journal of Medicine·K M McEvoyP A Low
Jan 31, 1995·Proceedings of the National Academy of Sciences of the United States of America·K OhnoA G Engel

❮ Previous
Next ❯

Citations

Jan 1, 2003·Muscle & Nerve·Andrew G EngelSteven M Sine
Aug 9, 2011·Journal of Neurology·Amina ChaouchHanns Lochmüller
Mar 20, 2002·Current Neurology and Neuroscience Reports·Kinji Ohno, Andrew G Engel
Oct 15, 2011·Current Neurology and Neuroscience Reports·Andrew G Engel
Aug 19, 2009·Journal of Molecular Neuroscience : MN·Andrew G EngelSteven M Sine
May 22, 2013·Neuromuscular Disorders : NMD·Anne-Kathrin PeyerDirk Fischer
Mar 31, 2007·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Andrew G Engel
Oct 23, 1998·Journal of Physiology, Paris·A G EngelS M Sine
Oct 10, 2012·Proceedings of the National Academy of Sciences of the United States of America·Michael WalogorskyPaul Brehm
Sep 1, 1999·Proceedings of the National Academy of Sciences of the United States of America·M ZhouA Auerbach
Dec 11, 1999·Current Opinion in Pediatrics·P B Andersson, T A Rando
Jul 21, 1998·Annals of the New York Academy of Sciences·A G EngelS M Sine
Jun 8, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Michael WalogorskyPaul Brehm
Jul 20, 2014·Neurologic Clinics·Jeffrey StatlandJaya R Trivedi
Jul 29, 2010·Current Opinion in Neurology·Hamid Sadeghian, Gil I Wolfe
Feb 23, 2012·Pediatric Neurology·Paulo José LorenzoniLineu Cesar Werneck
Nov 20, 2008·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Joseph H NogajskiP Ian Andrews
Nov 1, 2003·Annals of the New York Academy of Sciences·Andrew G EngelSteven M Sine
Apr 5, 2014·Journal of Molecular Recognition : JMR·Yan LiuLing Song
Apr 20, 2006·Neuromuscular Disorders : NMD·J ColomerH Lochmüller
Jun 2, 2015·Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie·S de la VaissièreP Castelnau
Nov 23, 2011·Neuromuscular Disorders : NMD·Andrew G Engel
Mar 31, 2004·Muscle & Nerve·John C Keesey
Mar 24, 2006·Nature·Steven M Sine, Andrew G Engel
Jul 20, 2006·International Anesthesiology Clinics·Gilmore N O'Neill
Jul 3, 2009·Luminescence : the Journal of Biological and Chemical Luminescence·Yanbo ZengGuonan Chen
May 3, 2003·Nature Reviews. Neuroscience·Andrew G EngelSteven M Sine
Sep 16, 2004·Current Opinion in Neurology·Daniel HantaïBruno Eymard
Jul 23, 2018·Current Treatment Options in Neurology·Constantine FarmakidisMazen M Dimachkie
Apr 2, 2019·Emerging Topics in Life Sciences·Rachel ThompsonHanns Lochmüller
Jul 27, 2017·Translational Neuroscience·Mohammad A Al-Muhaizea, Sulaiman Bazee Al-Mobarak
Jun 13, 2018·Current Neurology and Neuroscience Reports·Andrew G Engel
Jun 23, 2006·Arquivos de neuro-psiquiatria·Paulo José LorenzoniLineu César Werneck
Jan 31, 2018·Annals of the New York Academy of Sciences·Manon LeeJacqueline Palace
Dec 6, 2018·Frontiers in Pharmacology·Günter GisselmannHanns Hatt
Dec 6, 2020·Neurology·Brian D Stephens, Min K Kang

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.